Eisai Co., Ltd.

4523

JP3160400002

Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

2024-11-05 - Q2 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Eisai Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6,649 JPY

Average target price

8,271 JPY

Spread / Average Target

+24.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EISAI CO., LTD.	-6.72%	12.53B
ELI LILLY AND COMPANY	+48.53%	779B
NOVO NORDISK A/S	+40.67%	631B
JOHNSON & JOHNSON	-6.37%	354B
MERCK & CO., INC.	+20.93%	333B
ABBVIE INC.	+8.21%	301B
ASTRAZENECA PLC	+16.75%	249B
ROCHE HOLDING AG	-1.19%	216B
NOVARTIS AG	+10.85%	214B
AMGEN INC.	+4.40%	163B

Other Pharmaceuticals

Delayed Japan Exchange Other stock markets 08:19:12 2024-06-11 pm EDT			5-day change	1st Jan Change
6,580 ^JPY	-1.04%		-7.09%	-6.72%

Jun. 11	Japan's Nikkei gains on chip shares boost; Fed policy in focus	RE
Jun. 11	Japan's Nikkei rises on US stocks, heavyweight chip shares	RE

Japan's Nikkei gains on chip shares boost; Fed policy in focus	Jun. 11	RE
Japan's Nikkei rises on US stocks, heavyweight chip shares	Jun. 10	RE
FDA advisory panel votes in favor of data for Lilly Alzheimer's drug	Jun. 10	RE
US FDA advisers to review Eli Lilly Alzheimer's drug	Jun. 10	RE
Eisai Announces FDA Accepts Filing of Leqembi (Lecanemab-Irmb) sBLA for IV Maintenance Dosing for Treatment of Early Alzheimer's Disease	Jun. 09	CI
US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug	Jun. 06	RE
Eisai Starts Share Purchases Under 30 Billion Yen Buyback	Jun. 03	MT
BioArctic, Eisai's Azlheimer’s Disease Drug Wins Regulatory Nod in South Korea	May. 24	MT
Eisai's Attributable Profit Falls 23.5% in Fiscal 2024	May. 15	MT
BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing	May. 15	MT
Transcript : Eisai Co., Ltd., 2024 Earnings Call, May 15, 2024	May. 15
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA	May. 15	RE
Eisai Co., Ltd. announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.	May. 14	CI
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	May. 14	CI
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA	May. 14	RE
Eisai Co., Ltd. authorizes a Buyback Plan.	May. 14	CI
People with two copies of a risk gene have genetic form of Alzheimer's, scientists say	May. 06	RE
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Alzheimer's drug adoption in US slowed by doctors' skepticism	Apr. 23	RE
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	Apr. 20	CI
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	Apr. 01	MT
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01	MT
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	CI
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	Mar. 22	MT
Lifenet to Launch Dementia-Focused Insurance Product in April	Mar. 22	MT